SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 98.19 |
| Enterprise Value ($M) | 39.12 |
| Book Value ($M) | 41.22 |
| Book Value / Share | 0.46 |
| Price / Book | 2.38 |
| NCAV ($M) | 39.72 |
| NCAV / Share | 0.44 |
| Price / NCAV | 2.47 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -2.30 |
| Return on Assets (ROA) | -1.45 |
| Return on Equity (ROE) | -2.00 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.71 |
| Current Ratio | 2.71 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 63.27 |
| Assets | 64.76 |
| Liabilities | 23.54 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Rtw Investments, Lp | 6.10 | 29.05 | |
| 13G/A | Janus Henderson Group Plc | 5.70 | -23.81 | |
| 13G/A | Avidity Partners Management LP | 9.90 | 1.01 | |
| 13G | Adage Capital Management, L.P. | 6.21 | ||
| 13G/A | Vanguard Group Inc | 5.21 | 0.00 | |
| 13G/A | Commodore Capital Lp | 0.00 | -100.00 | |
| 13G/A | Deep Track Capital, LP | 0.00 | -100.00 | |
| 13G | Biotechnology Value Fund L P | 9.90 | ||
| 13G | Soleus Private Equity Fund III, L.P. | 8.10 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 242,255 | 979,663 | 24.73 | |
| 252,465 | 818,498 | 30.84 | |
| 400,001 | 1,356,289 | 29.49 | |
| 344,347 | 1,090,056 | 31.59 | |
| 262,544 | 2,192,547 | 11.97 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| IDYA – IDEAYA Biosciences, Inc. | IFRX – InflaRx N.V. |
| IGMS – IGM Biosciences, Inc. | IMVT – Immunovant, Inc. |
| INBX – Inhibrx Biosciences, Inc. |
Financial data and stock pages provided by
Fintel.io